Recommendation of the President – Carvykti (cyltacabtagen autoleucel)

On 29 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 207/2025 on the reimbursement of the medicinal product Carvykti (cyltacabtagen autoleucel) under the B.54 drug program. “Treatment of patients with multiple myeloma (ICD-10: C90.0)”

Publication in Public Information Bulletin (BIP) >>